Comparative Clinical Effectiveness and Safety of Super-Bioavailable Itraconazole and Conventional Itraconazole Capsules in the Management of Recalcitrant, Recurrent and Relapsing Superficial Dermatophytosis: An Analytical Interventional Study
International Journal of Current Pharmaceutical Review and Research · 30.06.2026 · 18 (06)
DOI: 10.25258/ijcpr.18.6.275 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.06.2026. Verfasst von Deepak Kumar und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
The rising prevalence of chronic, recurrent and relapsing dermatophytosis in India has become a major therapeutic challenge. Conventional itraconazole remains a commonly prescribed systemic antifungal agent; however, its variable absorption and bioavailability may affect treatment outcomes. Super-bioavailable itraconazole has been developed to overcome these pharmacokinetic limitations.
Objectives
To compare the clinical effectiveness and safety of super-bioavailable itraconazole and conventional itraconazole in the treatment of recalcitrant, recurrent and relapsing superficial dermatophytosis.
Methods
A prospective analytical interventional study was conducted among 100 adult patients with KOHconfirmed superficial dermatophytosis. Patients received either conventional itraconazole 200 mg once daily or super-bioavailable itraconazole 130 mg once daily for four weeks. Clinical effectiveness was assessed using Total Symptom Score (TSS) and Extent of Lesion Score. Safety was evaluated by recording adverse events. Patients achieving significant cure were followed for recurrence over an additional four weeks.
Results
Ninety patients completed the treatment phase. At week 4, significant clinical cure was observed in 58% of patients receiving super-bioavailable itraconazole compared with 36% receiving conventional itraconazole (p=0.03). Mean reduction in TSS was greater in the super-bioavailable itraconazole group (ΔTSS=5.23) than in the conventional itraconazole group (ΔTSS=4.38). Both treatments were well tolerated, with only mild gastrointestinal adverse events reported. Recurrence was observed in both groups without a statistically significant difference.
Conclusion
Super-bioavailable itraconazole demonstrated superior clinical effectiveness compared with conventional itraconazole while maintaining a comparable safety profile.
Zitieren
APA
Kumar, D., Pravakar, P. P., Hussain, M. M., & Kumari, S. (2026). Comparative Clinical Effectiveness and Safety of Super-Bioavailable Itraconazole and Conventional Itraconazole Capsules in the Management of Recalcitrant, Recurrent and Relapsing Superficial Dermatophytosis: An Analytical Interventional Study. International Journal of Current Pharmaceutical Review and Research, 18(06). https://doi.org/10.25258/ijcpr.18.6.275
Vancouver
Kumar D, Pravakar PP, Hussain MM, Kumari S. Comparative Clinical Effectiveness and Safety of Super-Bioavailable Itraconazole and Conventional Itraconazole Capsules in the Management of Recalcitrant, Recurrent and Relapsing Superficial Dermatophytosis: An Analytical Interventional Study. International Journal of Current Pharmaceutical Review and Research. 2026;18(06). doi:10.25258/ijcpr.18.6.275
BibTeX
@article{Kumar2026,
author = {Kumar, Deepak and Pravakar, Prem Prakash and Hussain, Md. Mobarak and Kumari, Shikha},
title = {Comparative Clinical Effectiveness and Safety of Super-Bioavailable Itraconazole and Conventional Itraconazole Capsules in the Management of Recalcitrant, Recurrent and Relapsing Superficial Dermatophytosis: An Analytical Interventional Study},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {06},
doi = {10.25258/ijcpr.18.6.275}
}
EUVIMED